[A15-50] Nivolumab - Addendum to Commission A15-27

Last updated 07.01.2016

Project no.:

Commission awarded on 25.11.2015 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:
Skin and hair, Cancer


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


Nivolumab in melanoma: data subsequently submitted improve assessment result

The extent of added benefit increased to "considerable" in women with BRAF V600 wt tumour, and to "major" in men

Federal Joint Committee (G-BA)

2016-01-07 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.